Physician profile
Joseph E Gerhardstein
NPI 1790780286
$5,352.27
in general payments reported to CMS, 2019-2025
45 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,633 · 2020: $199 · 2021: $547 · 2022: $724 · 2023: $824 · 2024: $752 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.58 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $796.94 | 2019-2025 | |
| Lilly USA, LLC | $489.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $471.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $434.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $354.21 | 2019-2022 | |
| Esperion Therapeutics, INC. | $315.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $297.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $184.52 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $181.39 | 2019-2025 | |
| Abbott Laboratories | $162.57 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Antares Pharma, INC. | $137.41 | 2021-2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $134.33 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $122.38 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $113.53 | 2019-2025 | Rexulti |
| Amarin Pharma, INC. | $111.33 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gerhardstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.